FDA Brief

Warning letters Drugs

FDA warning letter to

D&H Medical Services

LowIssued Jun 8Posted Jun 16Center for Drug Evaluation and Research (CDER)

FDA warned D&H Medical Services that its website falsely suggests its compounded semaglutide and tirzepatide are the same as FDA-approved brand drugs.

What happened

FDA reviewed the company's website, https://www.dhmedicalcenter.com (Establishment Identifier 3044174854), in March 2026 and found it offers compounded semaglutide and tirzepatide drug products. The site states "Same ingredient as Ozempic®, Rybelsus®, Mounjaro®," which FDA says implies the compounded products are FDA-approved or have been evaluated for safety and effectiveness when they have not. FDA cited this as misbranding under the FD&C Act.

What FDA found

  1. The website tells customers its compounded semaglutide and tirzepatide are the "same ingredient as" Ozempic, Rybelsus and Mounjaro, which misleadingly implies FDA approval.

    FD&C Act sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]
  2. Compounded drugs are not FDA-approved, so labeling that suggests approval is false or misleading.

    FD&C Act section 502(a) [21 U.S.C. § 352(a)]
  3. Advertising or promoting a compounded drug with false or misleading statements misbrands the product.

    FD&C Act section 502(bb) [21 U.S.C. § 352(bb)]
  4. Shipping these misbranded drugs across state lines is a prohibited act.

    FD&C Act section 301(a) [21 U.S.C. § 331(a)]
  5. Receiving, delivering or offering to deliver misbranded drugs is also prohibited.

    FD&C Act section 301(c) [21 U.S.C. § 331(c)]
  6. Compounded drugs must meet the conditions of sections 503A or 503B to be exempt from the new drug approval requirements.

    FD&C Act sections 503A and 503B [21 U.S.C. §§ 353a, 353b]

What FDA wants

FDA tells the company to email a written response to its Office of Compounding Quality and Compliance within 15 business days, identifying who makes the compounded products, providing sample labeling, and correcting or removing the misleading website claims. If the company cannot finish in that time, it must say why and give a date when it will.

Who should pay attention

  • telehealth and online pharmacy sites selling compounded GLP-1 drugs
  • compounding pharmacies whose products are marketed by others
  • marketing and compliance staff who write drug claims for websites

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Bella’s Nutri Shop Inc.

    Bella’s Nutri Shop sells “Tawon Liar” as an unapproved drug with hidden dexamethasone, tapentadol, and meloxicam.

    High risk
  4. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low